Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard- vs Micro-Dose rhBMP-2 for Dental Implant Stability
NCT07696299Not yet recruiting
- Sponsor
- University of Baghdad
- Start
- Dec 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial of recombinant human bone morphogenetic protein-2 gel in tooth loss (3 arms), sponsored by University of Baghdad. Primary endpoint: Peri-Implant Stability at 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
recombinant human bone morphogenetic protein-2 gel
03
Conditions
tooth loss
Beyond the preview
Go deeper on NCT07696299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07696299.